Pittsburgh, PA, United States
Pittsburgh, PA, United States

Time filter

Source Type

Patent
ChemImage Biothreat LLC | Date: 2017-01-09

The present disclosure provides systems and methods for determining the presence of a target material in a sample. In general terms, the system and method disclosed herein provide collecting interacted photons from a sample having a target material. The interacted photons are passed through a tunable filter to a VIS-NIR detector where the VIS-NIR detector generates a VIS-NIR hyperspectral image representative of the filtered interacted photons. The hyperspectral image of the filtered interacted photons is analyzed by comparing the hyperspectral image of the filtered interacted photons to known hyperspectral images to identify the presence of a target material in a sample. The systems and methods disclosed herein provide easy identification of the presence of a target material in a sample.


Patent
ChemImage Biothreat LLC | Date: 2014-04-07

The present disclosure describes security screening systems and methods for identifying a suspect material in a sample. In general terms, the system and method disclosed herein provide collection optics configured to collect a first plurality of interacted photons from an illuminated sample and generating a first optical signal. The first optical signal is separated into a plurality of optical components where the plurality of optical components are filtered by a plurality of filters. Each filter of the plurality of filters is configured to filter the plurality of optical components into a passband wavelength to generate a plurality of filtered components. The plurality of filtered components are detected by one or more detectors and one or more wavelength specific spectral images are generated. A processor is configured to analyze the one or more wavelength specific spectral images in order to identify the suspect material in the sample. The systems and methods disclosed herein may find particular use in a security setting.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 123.50K | Year: 2015

DESCRIPTION provided by applicant ChemImage Corporation a Tibbetts Award recipient in collaboration with GastroIntestinal Associates and the Allegheny Center for Digestive Health proposes a disruptive technology based on high throughput Raman Molecular Imaging RMI spectroscopy for colorectal cancer CRC diagnosis called the Raman Assay for Colorectal Cancer RACC RMI involves the collection and evaluation of spatially resolved Raman spectra using supervised multivariate statistical analysis i e chemometric techniques In preliminary Pilot Studies RACC has been able to detect subtle changes in dried blood serum composition and protein conformation without the use of chemical reagents RACC can differentiate between biobanked blood serum samples from patients with colorectal cancer versus those who are disease free with sensitivity and specificity of approximately Pilot studies conducted to date suggest RACC is sensitive to early stage CRC and the presence of polyps including advanced adenomas and if validated as technically and clinically feasible RACC would have commercial value as a CRC screening in vitro diagnostic IVD assay In this proposed project which is relevant to the mission of the National Cancer Institute ChemImage anticipates undertaking the first demonstration of the technical and clinical feasibility of RACC applied to fresh clinical blood serum samples The longer term objective and intended use of the RACC Test will be as an aid in screening patients for pre cancerous polyps and CRC The RACC Test will be used by health care professionals who screen for CRC including gastroenterologists and primary care physicians In this Phase study RMI spectroscopy will be performed at low throughput using a Raman microscope operating with nm laser excitation without the use of reagents In its mature commercial form the RACC Test would be performed on a high throughput RACC instrument enabled by automated detection algorithms and software in min per dried blood serum sample to minimize cost per assay If validated for Intended Use as a CRC screening assay we anticipate RACC will undergo Food and Drug Administration FDA premarket approval PMA and will require Centers for Medicare andamp Medicaid Services CMS National Coverage Decision ChemImage has assembled a Regulatory Affairs andamp Reimbursement Advisory Group with participation of experienced consultants having years of past experience within the FDA CDRH Office of IVD andamp Radiological Health and CMS whose goal is to increase the likelihood of successful commercialization RACC has the potential to provide the detection performance approaching colonoscopy at costs comparable to fecal occult blood tests FOBT because it operates without the use of costly reagents Since RACC would be applicable to blood serum samples it is anticipated to have a very high compliance rate among target patient populations and as a result improve the quality of care and reduce the cost of managing CRC disease Also of significance as CRC disproportionally affects African American patients the successful development of this assay would help reduce this healthcare disparity PUBLIC HEALTH RELEVANCE The Raman Assay for Colorectal Cancer RACC involves the application of Raman molecular imaging RMI spectroscopy to the analysis of blood serum samples Preliminary results obtained from bio bank samples indicate excellent discrimination performance approaching sensitivity and specificity for the detection of colorectal cancer CRC but technical feasibility for application to fresh clinical samples needs to be established If successful RACC will be optimized in a high throughput configuration to provide a cost effective in vitro diagnostics capability that will improve the quality of care in CRC screening an disease management


Grant
Agency: Department of Defense | Branch: Defense Advanced Research Projects Agency | Program: SBIR | Phase: Phase I | Award Amount: 154.95K | Year: 2015

A reconfigurable, small form factor, cost effective, infrared hyperspectral imaging system capable of operating in real-time is required for a broad array of missions to detect a variety of threats under dynamic operating conditions. The solution is the Reconfigurable Conformal Imaging Sensor (RCIS). RCIS is a high frame rate, multivariate hyperspectral imaging tool for use in dynamic threat environments. Based on target-agile sensor architecture, it will have revolutionary sensing capability to address the Warfighters key performance gaps. Real-time detection is facilitated through the use of the imaging spectrometer, known as a conformal filter (CF). A CF is a novel multivariate hyperspectral imaging methodology that uses elements of commercial-grade liquid crystal tunable filters, and also relies on validated manufacturing processes. Unlike an LCTF which is engineered to transmit one (1) optical passband at a time, the CF is designed to simultaneously transmit multiple optical passbands. The electro-optic selection of optical passbands is optimized for the discrimination of targets versus complex backgrounds. In operation, the CF mimics the performance of conventional hyperspectral imaging operation, which can involve hundreds of discrete measurements, and reduces it to two (2) measurements, thus increasing speed of detection and throughput.


Grant
Agency: National Aeronautics and Space Administration | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 124.92K | Year: 2014

ChemImage Sensor Systems (CISS), teaming with the University of South Carolina, proposes a revolutionary wide-field Raman hyperspectral imaging system capable of meeting the stated needs. The proposed innovation couples a spatial heterodyne spectrometer (SHS), a novel slit-less spectrometer that operates similar to Michelson interferometer, with a fiber array spectral translator (FAST) fiber array, a two-dimensional imaging fiber for hyperspectral imagery, to create a novel wide-field, high throughput Raman hyperspectral imager capable of yielding very high spectral resolution in a small form factor. The system can be configuredin both benchtop and standoff configurations. A standoff configuration is beneficial for any rover based mission, since it does not require close contact to the analyte of interest and Raman can interrogate targets up to 100 meters away.


Patent
ChemImage Biothreat LLC | Date: 2013-10-16

A method for detecting unknown materials, such as drugs. A first location is surveyed using a video capture device to identify a second location comprising an unknown material. The second location is interrogated using SWIR spectroscopic and/or imaging methods to generate a SWIR hyperspectral image. The SWIR hyperspectral image is analyzed to associate the unknown material with a known drug material. A system for detecting unknown materials, such as drugs comprising a first collection lens for collecting interacted photons from a first location and a visible imaging device for generating a visible image. A second collection lens may collect a plurality of interacted photons from a second location and a tunable filter may filter the interacted photons. A spectroscopic imaging device may detect the interacted photons and generate a SWIR hyperspectral image. A processor may analyze the SWIR hypespectral image to associate an unknown material with a known material.


Patent
ChemImage Biothreat LLC | Date: 2013-10-16

A portable system and method for detecting drug materials. A portable system may comprise at least one collection lens for collecting a plurality of interacted photons, a tunable filter for filtering the photons, and a SWIR detector for generating at least one SWIR data set representative of a first location comprising an unknown sample. A processor may analyze the SWIR data set to associate the unknown material with a known drug material. A method may comprise collecting a plurality of interacted photons, filtering the interacted photons into a plurality of wavelength bands, detecting the filtered photons to generate a SWIR data set and analyzing the SWIR data set to associate an unknown material with a known drug material.


Devices, systems, and methods for distinguishing tissue types are described herein. Such devices and systems may use dual polarization, conformal filters to acquire image data from target tissues and a processor to create an image in which the contrast between tissues has been enhanced.


Patent
ChemImage Biothreat LLC | Date: 2013-11-06

A system and method for analyzing biological samples, such as dried human blood serum, to determine a disease state such as colorectal cancer (CRC). Using dried samples may hold potential for enhancing localized concentration and/or segmentation of sample components. The method may comprise illuminating at least one location of a biological sample to generate a plurality of interacted photons, collecting the interacted photons and generating at least one Raman data set representative of the biological sample. A system may comprise an illumination source to illuminate at least one location of a biological sample and generate at least one plurality of interacted photons, at least one mirror for directing the interacted photons to a detector. The detector may be configured to generate at least one Raman data set representative of the biological sample. The system and method may utilize a FAST device for multipoint analysis or may be configured to analyze a sample using a line scanning configuration.


The present disclosure provides for a system and method for analyzing a sample comprising at least one unknown material. A first location may be scanned to generate a SWIR hyperspectral image. The SWIR hyperspectral image may be generated using dual polarization techniques. The SWIR hyperspectral image may be analyzed to target a second location comprising the unknown material. This second location may be further analyzed using Raman spectroscopic techniques and a Raman data set may be generated. The Raman data set may be further analyzed to associate the unknown material with a know material.

Loading ChemImage Biothreat LLC collaborators
Loading ChemImage Biothreat LLC collaborators